therapeutic autologous dendritic cells
Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer
Ifinatamab Deruxtecan, Small Cell Lung Cancer, Phase 2 Trial, ADC Technology, Daiichi Sankyo, Merck
Duality Biotherapeutics Files for Hong Kong IPO, Expanding ADC Therapeutics Portfolio
Duality Biotherapeutics, Hong Kong IPO, ADC Therapeutics, BioNTech, BeiGene, Cancer Treatment
WuXi Biologics’ ADC Spinout Sees Revenue Surge Amid Biosecure Threat
WuXi Biologics, ADC spinout, revenue jump, Biosecure risk, CRDMO, bioconjugate market
Adcendo Secures $1 Billion Deal for Multitude’s Anti-TF ADC
Adcendo, Multitude Therapeutics, anti-TF ADC, $1 billion deal, biobucks, antibody-drug conjugate, cancer treatment
FDA Clears BioNTech-MediLink ADC Trial to Resume with Reduced Doses
BioNTech, MediLink, ADC trial, FDA approval, lower doses, cancer treatment, HER3, patient safety
IDEAYA Secures $400M Option Deal with Biocytogen for Bispecific ADC
IDEAYA Biosciences, Biocytogen, Bispecific ADC, Option Deal, Cancer Treatment
Myricx Bio Secures £90m ($114m) Series A Financing to Advance Novel NMTi ADC Therapeutics
Myricx Bio, Series A Financing, NMTi ADC Therapeutics, Novo Holdings, Lilly, Cancer Treatment
Daiichi Sankyo Secures $47 Million Victory in ADC Patent Arbitration Against AstraZeneca
Daiichi Sankyo, AstraZeneca, ADC Patent Arbitration, $47 Million Settlement
FDA Rejects Merck-Daiichi’s HER3-Targeted ADC Due to Manufacturing Issues
FDA, Merck, Daiichi Sankyo, HER3-targeted ADC, patritumab deruxtecan, manufacturing concerns, lung cancer treatment
FDA Halts BioNTech-MediLink ADC Trial Due to ‘Significant Risk of Illness or Injuries’
FDA, BioNTech, MediLink, ADC, Clinical Trial, Safety Concerns, Cancer Treatment